A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Incyte Corporation
- Study ID
- NCT07623200
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Essential Thrombocythemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- INCA033989 — DRUGAdministered intravenous (IV) in accordance with the protocol-defined requirements.
- Best Available Treatment — DRUGBest Available Therapy (BAT) will be selected by the investigator.
Study Details
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
Key Dates
- First listed
- Jun 3, 2026
- Start date
- Sep 8, 2026
- Status verified
- Aug 2026
- Primary completion
- Jun 15, 2029
- Completion
- Nov 1, 2030
Study Design
- Enrollment
- 426 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: INCA033989Administered intravenous (IV) in accordance with the protocol-defined requirements.
- Experimental: Best Available Therapy (BAT)Best Available Therapy (BAT) will be selected by the investigator.
Primary Outcome Measure
Durable clinicohematologic response (DCR) [ Time Frame: Week 24 ]
Central Contacts
- Incyte Corporation Call Center (US)1.855.463.3463
- Incyte Corporation Call Center (ex-US)+800 00027423
Locations (44)
Find similar trials in Gilbert, AZ
Related Studies
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsPHASE2 · Recruiting · University of Washington · Seattle, Washington
- Ruxolitinib in Thrombocythemia and Polycythemia VeraPHASE2 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative NeoplasmPHASE1 · Recruiting · Marina Kremyanskaya · New York, New York
- Two Step Haplo With Radiation ConditioningPHASE2 · Recruiting · Thomas Jefferson University · Philadephia, Pennsylvania